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Background
In previously treated patients with metastatic renal cell
carcinoma (mRCC), the programmed death-1 (PD-1)
inhibitor antibody nivolumab demonstrated objective
response rates of 20%–22% and median overall survival
(OS) of 18.2– 25.5 months[1]. An exploratory biomarker
analysis of baseline and on-therapy changes was con-
ducted to investigate the relationship between the clinical
and immunomodulatory activity of nivolumab.
Methods
Patients with 1–3 prior therapies for mRCC received nivo-
lumab 0.3, 2, or 10 mg/kg IV every 3 weeks (Q3W); treat-
ment-naïve patients received 10 mg/kg IV Q3W. Biopsies
and peripheral blood mononuclear cells were obtained at
baseline and cycle 2 day 8. Tumor burden reduction was
defined as a ≥20% decrease. Gene expression data were
obtained on Affymetrix U219. OS parameters were esti-
mated by the Kaplan-Meier method or by Cox proportional
hazards regression. PD-1 ligand 1 (PD-L1) expression was
measured by tumor membrane immunohistochemical
staining (28-8 antibody; Dako) in baseline biopsies. Serum-
soluble factors were quantified using a Luminex multiplex
panel (Myriad Rules-Based Medicine). T cell receptor
sequencing was conducted with the immunoSEQ assay
(Adaptive Biotechnologies).
Results
91 patients were treated. 59 baseline and 55 on-therapy
biopsies were evaluable for gene expression, with 42
matched samples. Patients with tumor burden reduction
had differential expression (>1.3-fold, P < 0.01, q-value <
0.16) of 311 genes at baseline (n = 13) and 779 genes on-
therapy (n = 11) compared with patients without tumor
burden reduction, including higher expression of tran-
scripts associated with cell-mediated immunity. CTLA-4,
TIGIT, and PD-L2 transcripts were present at higher
levels on-therapy in patients with tumor burden reduction.
Table 1 summarizes OS and OS by PD-L1 expression.
18/56 biopsies (32%) had ≥5% PD-L1 expression. Among
serum-soluble factors, recognized prognostic markers
(VEGF, ICAM1, VCAM1, TIMP1) were associated with
OS. Based on T cell sequencing, increased tumor T cell
counts and decreased blood T cell clonality at baseline
were associated with longer OS.
Conclusions
Immune markers at baseline and on-therapy suggest pre-
existing adaptive immunity is associated with nivolumab-
induced tumor regression. Upregulation of immune
checkpoint molecules provides rationale for study of
nivolumab and ipilimumab combination in mRCC. A
minimal difference in OS by PD-L1 expression was
observed for up to 2 years.
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Table 1
Median OS, mo (95% CI) OS rate, % (95% CI)
1-yr 2-yr
Treatment group
0.3 mg/kg (n=22) 16.4 (10.1-NR) 71 (47-86) 44 (22-64)
2.0 mg/kg (n=22) NR 72 (48-86) 61 (36-78)
10 mg/kg (n=23) 25.2 (12.0-NR) 74 (48-88) 51 (27-71)
10 mg/kg (naïve) (n=24) NR 81 (57-92) 76 (51-89)
PD-L1 expression
≥5% (n=18) NR 71 (44-87) 64 (37-82)
<5% mg/kg (n=38) 23.4 (13.1-33.3) 71 (52-83) 48 (30-64)
NR = not reached
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